ReviewClinical science (London, England : 1979)2013
Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease.
Review in Clinical science (London, England : 1979), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis.Stem cell research & therapy · 2020Pooled it
- Mesenchymal stem cell-derived exosomes in myocardial infarction repair: therapeutic potential and scaffold-based delivery strategies.Frontiers in pharmacology · 2026Review
- Network Pharmacology Approaches to Myocardial Infarction Reperfusion Injury: Exploring Mechanisms, Pathophysiology, and Novel Therapies.Biomedicines · 2025Review
- Review
- Stage-specific regulation of signalling pathways to differentiate pluripotent stem cells to cardiomyocytes with ventricular lineage.Stem cell research & therapy · 2022Article
- 3-Dimensional Bioprinting of Cardiovascular Tissues: Emerging Technology.JACC. Basic to translational science · 2021Review
- Regulation of cardiomyocyte maturation during critical perinatal window.The Journal of physiology · 2020Review
- The Potential of Stem Cells and Stem Cell-Derived Exosomes in Treating Cardiovascular Diseases.Journal of cardiovascular translational research · 2019Review
- Establishment of A Protocol for In Vitro Culture of Cardiogenic Mesodermal Cells Derived from Human Embryonic Stem Cells.Cell journal · 2019Article
- Human iPSC-Derived Posterior Gut Progenitors Are Expandable and Capable of Forming Gut and Liver Organoids.Stem cell reports · 2018Article
- Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles.Frontiers in pharmacology · 2018Review
- Article
- Therapeutic applications of adipose-derived stem cells in cardiovascular disease.American journal of stem cells · 2018Review
- Cardiac progenitor cells: old is not always gold.The Journal of physiology · 2017Article
- Article
- Microtissues in Cardiovascular Medicine: Regenerative Potential Based on a 3D Microenvironment.Stem cells international · 2016Review
- Susceptibility of murine induced pluripotent stem cell-derived cardiomyocytes to hypoxia and nutrient deprivation.Stem cell research & therapy · 2015Article
- Pluripotent Stem Cell Therapy in Ischemic Cardiovascular Disease.Acta Cardiologica Sinica · 2014Review
- Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells.Stem cell research & therapy · 2014Review
- Pregnancy-induced physiological hypertrophy protects against cardiac ischemia-reperfusion injury.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Stem cell therapy has emerged as a promising strategy for cardiac and vascular repair. The ultimate goal is to rebuild functional myocardium by transplanting exogenous stem cells or by activating native stem cells to induce endogenous repair. CS/PCs (cardiac stem/progenitor cells) are one type of adult stem cell with the potential to differentiate into cardiac lineages (cardiomyocytes, smooth muscle cells and endothelial cells). iPSCs (induced pluripotent stem cells) also have the capacity to differentiate into necessary cells to rebuild injured cardiac tissue. Both types of stem cells have brought promise for cardiac repair. The present review summarizes recent advances in cardiac cell therapy based on these two cell sources and discusses the advantages and limitations of each candidate. We conclude that, although both types of stem cells can be considered for autologous transplantation with promising outcomes in animal models, CS/PCs have advanced more in their clinical application because iPSCs and their derivatives possess inherent obstacles for clinical use. Further studies are needed to move cell therapy forward for the treatment of heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.